TRCT
ARLZ

Tower Research Capital (TRC)’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,916
Closed -$7K – 4338
2017
Q4 		$7K Buy
4,916
+3,516
+251% +$5.77K ﹤0.01% 2784
2017
Q3 		$4K Buy
1,400
+1,100
+367% +$1.47K ﹤0.01% 3454
2017
Q2 		$1K Sell
300
-21,576
-99% -$31.2K ﹤0.01% 2613
2017
Q1 		$47K Buy
21,876
+20,675
+1,721% +$77.7K ﹤0.01% 771
2016
Q4 		$7K Sell
1,201
-1,298
-52% -$6.16K ﹤0.01% 2917
2016
Q3 		$12K Sell
2,499
-11,890
-83% -$54.2K ﹤0.01% 1986
2016
Q2 		$47K Buy
+14,389
New +$54.3K ﹤0.01% 1606

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return

Tower Research Capital (TRC)'s ARLZ Position: Q1 2018 in Review

Tower Research Capital (TRC) sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2018, closing a stake of 4,916 shares — an estimated $7K sold.

Tower Research Capital (TRC) first reported a position in ARLZ in Q2 2016 and held it in 7 quarters. The position peaked at $47K in Q1 2017. 56 funds tracked by Wall St. Rank hold ARLZ as of Q1 2018.

  • Tower Research Capital (TRC) reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 4,916 Aralez Pharmaceuticals Inc. shares in Q1 2018, an estimated $7K.
  • Tower Research Capital (TRC) first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s Aralez Pharmaceuticals Inc. position peaked at $47K in Q1 2017.
  • 56 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2018.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2018, filed 15 May 2018.